Imagio (breast cancer diagnostic system)

2021: Start of sales of a diagnostic system of breast cancer of Imagio

At the end of January, 2021 the American company Seno Medical announced the beginning of sales of a system of optico-acoustic visualization of Imagio which allows to distinguish good-quality or malignant damages of a breast using the special software. It is supposed that this noninvasive and radiationless technology will help to reduce the number of biopsiyny researches of a breast.

Start of sales of diagnostic systems of breast cancer of Imagio

Optico-acoustic visualization combines ultrasonography with laser optics, thereby providing doctors with the combined image of fabrics and a blood-groove in real time. Cancer defeats are usually characterized by the high density of again formed blood vessels (angiogenesis) and lower saturation by oxygen in comparison with surrounding fabrics. The Imagio system allows radiologists to look at these parameters in real time, and the accompanying software on the basis of AI under the name SenoGram helps to distinguish malignant and good-quality damages of a breast.

The medical director of Seno Medical doctor Tom Stavros in the press release noted that optimization of diagnostics of new growths of a breast requires a combination of very high sensitivity (≥98%) to simultaneous increase in specificity and minimization of false positive results and biopsies of benign tumors. However improvement of specificity when using other methods often happens due to decrease in desirable sensitivity. These researches PMA show that the Imagio system successfully reached high specificity at the fixed sensitivity of 98%, i.e. those parameters which allow to make the justified clinical decisions on need of a biopsy.^[1]

Notes